go-v.orgdoi

Rosuvastatin: Just Another Statin?

— · The Internet Journal of Cardiology · 2004

  • DOI 10.5580/21be
  • Publisher OpenAlex
  • Type article
  • Issued 2004

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

The Internet Journal of Cardiology · OpenAlex · article · 2004

Abstract

Convincing evidence exists supporting the major role HMG Co-A reductase inhibitors (statins) play in both primary and secondary prevention of cardiovascular diseases given, among other effects, their essential role in the reduction of LDL-C cholesterol . Recently revised guidelines recommend even more intense management of LDL-C cholesterol especially in moderate and high risk patients. Rosuvastatin, the newest statin, offers the most beneficial effects on the lipid profile and particularly, LDL-C. Its safety profile, both pre-approval and post-approval, at the current FDA-doses of 5-40mg is similar to other available statins.

Thus, rosuvastatin is an extremely helpful addition to the lipid armamentarium when prescribed at the current FDA approved doses.

Open the resolved locator · 10.5580/21be

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 16:19 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
http://doi.org/10.5580/21be
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.